An evaluation of COVID-19 serological assays informs future diagnostics and exposure assessment

The world is entering a new era of the COVID-19 pandemic in which there is an increasing call for reliable antibody testing. To support decision making on the deployment of serology for either population screening or diagnostics, we present a detailed comparison of serological COVID-19 assays. We sh...

Celý popis

Uloženo v:
Podrobná bibliografie
Vydáno v:Nature communications Ročník 11; číslo 1; s. 3436 - 5
Hlavní autoři: GeurtsvanKessel, Corine H., Okba, Nisreen M. A., Igloi, Zsofia, Bogers, Susanne, Embregts, Carmen W. E., Laksono, Brigitta M., Leijten, Lonneke, Rokx, Casper, Rijnders, Bart, Rahamat-Langendoen, Janette, van den Akker, Johannes P. C., van Kampen, Jeroen J. A., van der Eijk, Annemiek A., van Binnendijk, Rob S., Haagmans, Bart, Koopmans, Marion
Médium: Journal Article
Jazyk:angličtina
Vydáno: London Nature Publishing Group UK 06.07.2020
Nature Publishing Group
Nature Portfolio
Témata:
ISSN:2041-1723, 2041-1723
On-line přístup:Získat plný text
Tagy: Přidat tag
Žádné tagy, Buďte první, kdo vytvoří štítek k tomuto záznamu!
Popis
Shrnutí:The world is entering a new era of the COVID-19 pandemic in which there is an increasing call for reliable antibody testing. To support decision making on the deployment of serology for either population screening or diagnostics, we present a detailed comparison of serological COVID-19 assays. We show that among the selected assays there is a wide diversity in assay performance in different scenarios and when correlated to virus neutralizing antibodies. The Wantai ELISA detecting total immunoglobulins against the receptor binding domain of SARS CoV-2, has the best overall characteristics to detect functional antibodies in different stages and severity of disease, including the potential to set a cut-off indicating the presence of protective antibodies. The large variety of available serological assays requires proper assay validation before deciding on deployment of assays for specific applications. SARS-CoV-2 is causing a global pandemic in which the implementation of serology can support decision making in different scenarios. Here, the authors compare the outcome of eight commercially available assays to virus neutralization and discuss their use in diagnostics and exposure assessment of SARS-CoV-2.
Bibliografie:ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 14
ObjectType-Article-2
ObjectType-Feature-1
content type line 23
ISSN:2041-1723
2041-1723
DOI:10.1038/s41467-020-17317-y